Clik here to view.
PCIファーマ・サービシズが英国トレデガー施設の開発・製造能力を拡大するための大規模投資を発表
フィラデルフィア (ビジネスワイヤ) — 世界規模で製薬／バイオ製薬アウトソーシングサービスを提供する一流企業のPCIファーマ・サービシズ（PCI）は本日、臨床供給および商業供給の両面において高薬理活性医薬品の製造・開発能力を強化すべく、英国ウェールズにある当社のトレデガー施設の拡張を開始したと発表しました。...
View ArticleClik here to view.
L&T Technology Services Ltd Develops the World’s First Cost-Effective Robotic...
BANGALORE, India L&T Technology Services Limited (BSE: 540115, NSE: LTTS), India’s leading pure-play engineering services company, was felicitated for its Robotic Endo-training Kit at the 8th...
View ArticleClik here to view.
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration...
View ArticleClik here to view.
Sales of “KIRIN iMUSE YOGURT & LEMON FLAVORED DRINK”, Which Began in Vietnam...
TOKYO Interfood Shareholding CO. (President: Yutaka Ogami) announced that “KIRIN iMUSE YOGURT & LEMON FLAVORED DRINK”, a product developed specifically for the Vietnamese market and which went...
View ArticleClik here to view.
Agreement With COFCO Biotechnology Sets Stage for Avivagen to Secure...
OTTAWA, Ontario Avivagen Inc. (TSXV:VIV) (“Avivagen”) has announced that it has entered into an agreement with the research subsidiary of COFCO Biotechnology Co. Ltd. (“COFCO”) pursuant to which...
View ArticleClik here to view.
Soteria AI Intends to File First Patent, Driving AI Gaming Assistant Into...
HONG KONG & SAN FRANCISCO Soteria AI, the company developing the first AI assistant for gaming, today announces that it is in the process of filing its first patent for an algorithm to help...
View ArticleClik here to view.
山东方坦思宣布与杨森制药达成许可协议将开发抗IL-17A单克隆抗体并使其商业化
2019年12月17日[美国东部时间 (美国商业资讯)– 山东方坦思生制药有限公司（“方坦思”）今日宣布与强生公司旗下的一家杨森制药公司（“杨森”）签订独家许可、开发和商业化协议，在中华人民共和国（“中国”）包括香港特别行政区（“香港”）、澳门特别行政区（“澳门”）、台湾区域（“台湾”） 和韩国开发含有抗IL-17A单克隆抗体的医药产品并使其商业化。...
View ArticleClik here to view.
Shandong Fontacea Announces License Agreement with Janssen to Develop and...
JINAN, Shandong, People’s Republic of China Shandong Fontacea Pharmaceutical Co. Ltd. (“Fontacea”) announced today that it has entered into an exclusive license, development and commercialization...
View ArticleClik here to view.
Company Profile for Shandong Fontacea Pharmaceutical Co. Ltd.
About Shandong Fontacea Pharmaceutical Co. Ltd. Fontacea is a biopharmaceutical company dedicated to research, development and commercialization of innovative medicines for the global market,...
View ArticleClik here to view.
Pacific Prime China Wins Two Cigna & CMB Awards
SHANGHAI Pacific Prime, a leading insurance intermediary, has received two awards from Cigna & CMB, including the “Year 2019 Best Contributor Award” and “10 Year Anniversary Long-Term...
View ArticleClik here to view.
Soteria AI计划申请首项专利以推动AI游戏助手进入医学研究
香港和旧金山 (美国商业资讯)–正在开发第一款游戏AI助手的公司Soteria AI今天宣布，它正在为一项帮助研究专业人员了解某些病毒变异方式和原因的算法申请首项专利。在Soteria首席科学家Devon Nobrega和Lu Wang博士完成了一项名为“基因密码子中单、双和三核苷酸替代的分析”(An Analysis of Single, Double, and Triple...
View ArticleClik here to view.
GIGXR Announces Acquisition of Immersive Learning Group
VENICE, Calif. GIGXR, Inc., announced today that it has acquired global mixed reality and immersive learning assets from Pearson PLC, the worlds learning company. This press release features...
View ArticleClik here to view.
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
Vantage 2020 Preview: Strong Sales and Product Launches Set the Stage for...
LONDON & BOSTON & TOKYO Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage...
View ArticleClik here to view.
Turnstone Biologics Announces Global Collaboration and License Agreement with...
NEW YORK Turnstone Biologics, a biotechnology company pioneering the development of engineered viral immunotherapies, today announced a strategic collaboration with Takeda Pharmaceutical Company...
View ArticleClik here to view.
Promega Corporation Enters License Agreement with MilliporeSigma to Access...
MADISON, Wis. Promega Corporation today announced it has signed a license agreement with MilliporeSigma, a leader in genome editing, to access MilliporeSigma’s foundational CRISPR genome-editing...
View ArticleClik here to view.
Boston’s XenoTherapeutics Prepares to Donate Xeno-Skin™ to Burn Victims of...
BOSTON XenoTherapeutics, Inc. a clinical-stage biotechnology company focused on immunogenomic reprogramming of swine organs and tissues for human use, announced their readiness to supply victims of...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line...
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals...
View ArticleClik here to view.
DAIKO Will Exhibit in CES 2020
TOKYO & OSAKA, Japan DAIKO hosts [JAPAN TECH] in cooperation with CREATIVE VISION and Filament. [JAPAN TECH] has chosen nine start-ups and supports their exhibition for CES 2020. This press...
View ArticleClik here to view.
心不全発症率の増加を抑制するための大規模なランダム化対照試験
ボストン （ビジネスワイヤ） — 心臓発作患者さんの治療方法を変えることで心不全発症率を低減させる有望な新療法を追究するピボタル多施設臨床試験が、現在進行中です。ST上昇型心筋梗塞（STEMI) ドア・ツー・アンローディング（DTU）ピボタルランダム化対照試験（STEMI...
View Article